Antimicrobial Resistance Laboratory Network | ARLN
Purpose
CDC’s AR Lab Network is an effort between U.S. healthcare facility labs and public health department labs, regional labs and the National Tuberculosis Molecular Surveillance Center and CDC.
The AR Lab Network works with laboratories nationwide to identify, track, and respond to emerging and enduring antimicrobial-resistant threats including, but not limited to:
Impact
The AR Lab Network is the first network in the nation providing comprehensive antimicrobial resistance testing of healthcare-associated infections (HAIs) and community-associated infections, fungal diseases, sexually transmitted diseases and drug-resistant Mycobacterium tuberculosis.
Collaboration from the local to national levels results in more rapid response for detecting antimicrobial resistance (AR). The network closes the gap between local capabilities and the data needed to combat AR by providing:
- Comprehensive lab capacity and infrastructure for antimicrobial-resistant pathogens (disease causing organisms) detection found in health care, the community and the environment.
- Quality data to drive response efforts to prevent AR infections and transmissions.
From 2017-2023 AR Lab Network labs screened and tested the following:
- 362.009 Total carbapenem-producing and -resistant isolates and samples
- 120,752 Carbapenem-resistant Enterobacterales isolates
- 88,384 Carbapenem-resistant Pseudomonas aeruginosa isolates
- 25,370 Carbapenem-resistant Acinetobacter baumannii isolates
- 127,503 Carbapenem-producing organism screenings
How labs work together
U.S. healthcare and clinical labs should work with their local or state public health department to submit isolates or specimens for testing. The public health lab should work with their regional lab. Labs will also work with CDC.
Lab type | Roles and how they work with the AR Lab Network |
---|---|
Healthcare Facility and Clinical Labs |
When a clinical lab suspects an organism of concern for antimicrobial resistance, they send the isolate to their public health lab. Submitting isolates provides opportunity for supplemental characterization, public health awareness of the AR threat (including public health support if local assistance is needed), and surveillance. |
Public Health Department Labs |
|
The AR Lab Network Regional Labs and National TB Center |
All seven regional labs perform core testing. Select regional labs provide additional testing to support nationwide needs, including receiving pathogens from other CDC funded activities like Neisseria gonorrhoeae isolates from the Gonococcal Isolate Surveillance Project (GISP) and Strengthening the United States Response to Resistant Gonorrhea (SURRG) program. The National TB Center is equipped to perform whole genome sequencing for M. tuberculosis isolates identified in the U.S. |
CDC |
|
AR Lab Network Stories
CDC and health departments work to expand drug-resistant gonorrhea surveillance to emergency rooms.
How it’s funded
CDC’s Antimicrobial Resistance Solutions Initiative (AR Solutions Initiative) invests in national infrastructure, including the AR Lab Network, to detect, respond, contain, and prevent resistant infections across healthcare settings, communities, the food supply, and the environment (water, soil).
Funding recipients
Funding through CDC’s AR Solutions Initiative supports all 50 state health departments, some cities, and territories. CDC also collaborates with other federal agencies, state and local health departments, patients, public health partners, and the private sector to address this threat.
link